ARTICLE | Finance
Kymera’s degradation toolbox
Why investors are backing protein degradation company Kymera with $65M series B
November 13, 2018 4:25 PM UTC
As the protein degradation space continues to gain traction, Kymera Therapeutics LLC has attracted interest from investors to the tune of $65 million to bring its first program to the clinic.
6 Dimensions Capital, Bessemer Venture Partners and Pfizer Ventures co-led Kymera’s B round with participation by fellow new investors MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, Aju IB Investment and existing investors Atlas Venture, Lilly Ventures and Amgen Ventures. ...